Lipitor Generics Could Come 15 Months Earlier Than Anticipated After Patent Deemed Invalid
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer says “technical defect” in patent could be corrected with U.S. Patent and Trademark Office.
You may also be interested in...
Pfizer Wins Lipitor Reversal
Patent office's decision blocks generic atorvastatin until 2010.
Pfizer Wins Lipitor Reversal
Patent office's decision blocks generic atorvastatin until 2010.
Pfizer Terminates Torcetrapib Program
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.